Published in J Biomed Biotechnol on June 28, 2010
Prostaglandin D2 activates group 2 innate lymphoid cells through chemoattractant receptor-homologous molecule expressed on TH2 cells. J Allergy Clin Immunol (2013) 1.47
Decreased serum level of IL-21 in new-onset systemic lupus erythematosus patients. Rheumatol Int (2013) 1.46
HIV-specific CD4 T cells and immune control of viral replication. Curr Opin HIV AIDS (2011) 1.16
Spleen tyrosine kinase (Syk) regulates systemic lupus erythematosus (SLE) T cell signaling. PLoS One (2013) 0.90
Induction of intestinal pro-inflammatory immune responses by lipoteichoic acid. J Inflamm (Lond) (2012) 0.85
IL-21 is a double-edged sword in the systemic lupus erythematosus-like disease of BXSB.Yaa mice. J Immunol (2013) 0.83
The current concept of T (h) 17 cells and their expanding role in systemic lupus erythematosus. Arthritis (2011) 0.81
IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature (2007) 16.59
IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol (2007) 16.21
Systemic lupus erythematosus. N Engl J Med (2008) 10.22
A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21. Nat Genet (2007) 8.50
A critical role for IL-21 in regulating immunoglobulin production. Science (2002) 7.09
IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. Nature (2008) 7.00
A fundamental role for interleukin-21 in the generation of T follicular helper cells. Immunity (2008) 6.41
A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity. Nature (2005) 6.31
Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature (2000) 5.86
A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet (2008) 5.85
Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu Rev Immunol (2008) 4.90
IL-21 is required to control chronic viral infection. Science (2009) 4.80
Follicular helper T cells: lineage and location. Immunity (2009) 4.75
Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J Exp Med (2005) 4.60
A vital role for interleukin-21 in the control of a chronic viral infection. Science (2009) 4.55
Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J Immunol (2004) 4.43
Follicular helper T cells are required for systemic autoimmunity. J Exp Med (2009) 4.25
Anomalous type 17 response to viral infection by CD8+ T cells lacking T-bet and eomesodermin. Science (2008) 4.04
IL-21R on T cells is critical for sustained functionality and control of chronic viral infection. Science (2009) 3.90
A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med (1999) 3.74
Cytokine-mediated regulation of human B cell differentiation into Ig-secreting cells: predominant role of IL-21 produced by CXCR5+ T follicular helper cells. J Immunol (2007) 3.47
ICOS-dependent extrafollicular helper T cells elicit IgG production via IL-21 in systemic autoimmunity. J Exp Med (2008) 3.39
The IL-21 receptor augments Th2 effector function and alternative macrophage activation. J Clin Invest (2006) 3.33
IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production. J Immunol (2007) 2.99
Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med (1995) 2.89
IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc reduces disease progression. J Immunol (2007) 2.71
Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease. Gastroenterology (2005) 2.52
A critical role for IL-21 receptor signaling in the pathogenesis of systemic lupus erythematosus in BXSB-Yaa mice. Proc Natl Acad Sci U S A (2009) 2.46
B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans. J Exp Med (2010) 2.42
Regulation of gut inflammation and th17 cell response by interleukin-21. Gastroenterology (2008) 2.38
Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum (2004) 2.23
The role of IL-21 in regulating B-cell function in health and disease. Immunol Rev (2008) 2.09
Distinct activation signals determine whether IL-21 induces B cell costimulation, growth arrest, or Bim-dependent apoptosis. J Immunol (2004) 2.07
IL-21 mediates suppressive effects via its induction of IL-10. J Immunol (2009) 2.00
Interleukin-21 inhibits dendritic cell activation and maturation. Blood (2003) 2.00
IL-21 up-regulates the expression of genes associated with innate immunity and Th1 response. J Immunol (2002) 1.89
Genetic association of interleukin-21 polymorphisms with systemic lupus erythematosus. Ann Rheum Dis (2007) 1.82
IL-21 receptor signaling is integral to the development of Th2 effector responses in vivo. Blood (2006) 1.79
IL-21 induces the apoptosis of resting and activated primary B cells. J Immunol (2003) 1.67
Genetic variants in the region harbouring IL2/IL21 associated with ulcerative colitis. Gut (2009) 1.65
IL-21 and T follicular helper cells. Int Immunol (2009) 1.54
B cells are required for lupus nephritis in the polygenic, Fas-intact MRL model of systemic autoimmunity. J Immunol (1999) 1.54
The Yin and Yang of interleukin-21 in allergy, autoimmunity and cancer. Curr Opin Immunol (2008) 1.51
Interleukin 21: a cytokine/cytokine receptor system that has come of age. J Leukoc Biol (2008) 1.48
Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. Nat Med (2009) 1.45
B cells as antigen presenting cells. Cell Immunol (2006) 1.40
A functional role for interleukin-21 in promoting the synthesis of the T-cell chemoattractant, MIP-3alpha, by gut epithelial cells. Gastroenterology (2006) 1.38
Spontaneous production of interleukin-10 by B lymphocytes and monocytes in systemic lupus erythematosus. Eur Cytokine Netw (1994) 1.35
Interleukin-21: a critical regulator of the balance between effector and regulatory T-cell responses. Trends Immunol (2008) 1.33
T- and B-cell abnormalities in systemic lupus erythematosus. Crit Rev Immunol (2005) 1.27
A polymorphism within IL21R confers risk for systemic lupus erythematosus. Arthritis Rheum (2009) 1.23
Elevated interleukin-21 correlated to Th17 and Th1 cells in patients with immune thrombocytopenia. J Clin Immunol (2009) 1.18
IL-21: an executor of B cell fate. J Immunol (2009) 1.18
Elevated production of B cell chemokine CXCL13 is correlated with systemic lupus erythematosus disease activity. J Clin Immunol (2009) 1.16
Interferon-gamma-expressing cells are a major source of interleukin-21 in inflammatory bowel diseases. Inflamm Bowel Dis (2010) 1.12
Treatment of BXSB-Yaa mice with IL-21R-Fc fusion protein minimally attenuates systemic lupus erythematosus. Ann N Y Acad Sci (2007) 1.07
A novel subpopulation of B-1 cells is enriched with autoreactivity in normal and lupus-prone mice. Arthritis Rheum (2009) 1.07
B cells in human and murine systemic lupus erythematosus. Curr Opin Rheumatol (2004) 1.02
IL-21 synergizes with IL-7 to augment expansion and anti-tumor function of cytotoxic T cells. Int Immunol (2007) 1.02
Interleukin-21 as a new therapeutic target for immune-mediated diseases. Trends Pharmacol Sci (2009) 1.00
Decreased expression of interleukin-21 receptor on peripheral B lymphocytes in systemic lupus erythematosus. Int J Mol Med (2005) 1.00
T-cell and B-cell signaling biomarkers and treatment targets in lupus. Curr Opin Rheumatol (2009) 0.94
Interleukin-21: biology and application to cancer therapy. Expert Opin Biol Ther (2008) 0.93
Molecular scanning of interleukin-21 gene and genetic susceptibility to type 1 diabetes. Hum Immunol (2007) 0.91
Testing for the association of the KIAA1109/Tenr/IL2/IL21 gene region with rheumatoid arthritis in a European family-based study. Arthritis Res Ther (2009) 0.90
Lessons from BXSB and related mouse models. Int Rev Immunol (2000) 0.89
A common exonic variant of interleukin21 confers susceptibility to atopic asthma. Int Arch Allergy Immunol (2008) 0.86
Involvement of ERK-1/2 in IL-21-induced cytokine production in leukemia cells and human monocytes. Cytokine (2008) 0.86
Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J Immunol (2004) 7.41
Immunity, inflammation, and allergy in the gut. Science (2005) 4.82
Regulation of gut inflammation and th17 cell response by interleukin-21. Gastroenterology (2008) 2.38
IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes. J Immunol (2007) 1.92
Smad7 controls resistance of colitogenic T cells to regulatory T cell-mediated suppression. Gastroenterology (2008) 1.88
Regulation of homeostasis and inflammation in the intestine. Gastroenterology (2011) 1.82
Cutting edge: trans-signaling via the soluble IL-6R abrogates the induction of FoxP3 in naive CD4+CD25 T cells. J Immunol (2007) 1.78
IL-23/IL-17 axis in IBD. Inflamm Bowel Dis (2010) 1.71
Aryl hydrocarbon receptor-induced signals up-regulate IL-22 production and inhibit inflammation in the gastrointestinal tract. Gastroenterology (2011) 1.55
IL-23-mediated regulation of IL-17 production in Helicobacter pylori-infected gastric mucosa. Eur J Immunol (2008) 1.53
IL-21 regulates experimental colitis by modulating the balance between Treg and Th17 cells. Eur J Immunol (2007) 1.49
Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. Nat Med (2009) 1.45
Characterization of IL-17A-producing cells in celiac disease mucosa. J Immunol (2010) 1.40
A functional role for interleukin-21 in promoting the synthesis of the T-cell chemoattractant, MIP-3alpha, by gut epithelial cells. Gastroenterology (2006) 1.38
Autocrine regulation of IL-21 production in human T lymphocytes. J Immunol (2008) 1.35
Involvement of interleukin-21 in the regulation of colitis-associated colon cancer. J Exp Med (2011) 1.27
Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3alpha. Blood (2008) 1.25
Functional modulation of Crohn's disease myofibroblasts by anti-tumor necrosis factor antibodies. Gastroenterology (2007) 1.19
Interleukin-25 inhibits interleukin-12 production and Th1 cell-driven inflammation in the gut. Gastroenterology (2009) 1.19
Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-beta1-mediated suppression of colitis. Gastroenterology (2006) 1.17
New players in the cytokine orchestra of inflammatory bowel disease. Inflamm Bowel Dis (2007) 1.15
Evidence for the role of interferon-alfa production by dendritic cells in the Th1 response in celiac disease. Gastroenterology (2007) 1.14
The tumor suppressor activity of IKKalpha in stratified epithelia is exerted in part via the TGF-beta antiproliferative pathway. Proc Natl Acad Sci U S A (2008) 1.12
Interferon-gamma-expressing cells are a major source of interleukin-21 in inflammatory bowel diseases. Inflamm Bowel Dis (2010) 1.12
Interleukin-23 and Th17 cells in the control of gut inflammation. Mediators Inflamm (2009) 1.10
Intestinal inflammation and colorectal cancer: a double-edged sword? World J Gastroenterol (2011) 1.09
IL-21 is highly produced in Helicobacter pylori-infected gastric mucosa and promotes gelatinases synthesis. J Immunol (2007) 1.08
The aryl hydrocarbon receptor in inflammatory bowel disease: linking the environment to disease pathogenesis. Curr Opin Gastroenterol (2012) 1.07
Cyclooxygenase-2-dependent and -independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid. Biochem Pharmacol (2007) 1.06
Protease-activated receptor-2 activation in gastric cancer cells promotes epidermal growth factor receptor trans-activation and proliferation. Am J Pathol (2006) 1.06
Interleukin-12 and Th1 immune response in Crohn's disease: pathogenetic relevance and therapeutic implication. World J Gastroenterol (2006) 1.04
Th17-related cytokines: new players in the control of chronic intestinal inflammation. BMC Med (2011) 1.03
Aryl hydrocarbon receptor and colitis. Semin Immunopathol (2013) 1.02
Inhibition of monocyte-derived inflammatory cytokines by IL-25 occurs via p38 Map kinase-dependent induction of Socs-3. Blood (2009) 0.99
Emerging role of IL-23/IL-17 axis in H pylori-associated pathology. World J Gastroenterol (2007) 0.99
Interleukin-21 triggers effector cell responses in the gut. World J Gastroenterol (2010) 0.98
Common immunologic mechanisms in inflammatory bowel disease and spondylarthropathies. World J Gastroenterol (2009) 0.98
Extracellular signal-regulated protein kinase mediates interleukin 17 (IL-17)-induced IL-8 secretion in Helicobacter pylori-infected human gastric epithelial cells. Infect Immun (2004) 0.98
IL-21 promotes skin recruitment of CD4(+) cells and drives IFN-γ-dependent epidermal hyperplasia. J Immunol (2011) 0.95
Distinct profiles of effector cytokines mark the different phases of Crohn's disease. PLoS One (2013) 0.94
Smad7 expression in T cells prevents colitis-associated cancer. Cancer Res (2011) 0.93
Inhibition of colitis by IL-25 associates with induction of alternatively activated macrophages. Inflamm Bowel Dis (2011) 0.92
Targeting interleukin-21 in inflammatory diseases. Expert Opin Ther Targets (2011) 0.92
Mechanisms of action of non-steroidal anti-inflammatory drugs (NSAIDs) and mesalazine in the chemoprevention of colorectal cancer. Int J Mol Sci (2013) 0.92
Molecular targets of TRAIL-sensitizing agents in colorectal cancer. Int J Mol Sci (2012) 0.91
Reduction of CD68+ macrophages and decreased IL-17 expression in intestinal mucosa of patients with inflammatory bowel disease strongly correlate with endoscopic response and mucosal healing following infliximab therapy. Inflamm Bowel Dis (2013) 0.90
Matrix metalloproteinases in necrotising enterocolitis. Pediatr Res (2003) 0.90
IL-21 as a therapeutic target in inflammatory disorders. Expert Opin Ther Targets (2014) 0.89
Breast milk lactoferrin regulates gene expression by binding bacterial DNA CpG motifs but not genomic DNA promoters in model intestinal cells. Pediatr Res (2006) 0.89
The dual role of Smad7 in the control of cancer growth and metastasis. Int J Mol Sci (2013) 0.88
Analysis of the cytokine profile in the duodenal mucosa of refractory coeliac disease patients. Clin Sci (Lond) (2014) 0.87
Interleukin-21 in chronic inflammatory diseases. Biofactors (2013) 0.87
Constitutive activation of the signal transducer and activator of transcription pathway in celiac disease lesions. Am J Pathol (2003) 0.87
Interleukin-12 drives the Th1 signaling pathway in Helicobacter pylori-infected human gastric mucosa. Infect Immun (2007) 0.87
Lactobacillus paracasei subsp. paracasei B21060 suppresses human T-cell proliferation. Infect Immun (2007) 0.87
Lesional accumulation of CD163-expressing cells in the gut of patients with inflammatory bowel disease. PLoS One (2013) 0.86
Compartmentalised expression of meprin in small intestinal mucosa: enhanced expression in lamina propria in coeliac disease. Biol Chem (2007) 0.86
Th17 cytokines in inflammatory bowel diseases: discerning the good from the bad. Int Rev Immunol (2013) 0.86
What's the next best cytokine target in IBD? Inflamm Bowel Dis (2012) 0.86
TGF-Beta signaling manipulation as potential therapy for IBD. Curr Drug Targets (2013) 0.85
Interleukin-21 (IL-21) controls inflammatory pathways in the gut. Endocr Metab Immune Disord Drug Targets (2007) 0.85
Disruption of inflammatory signals by cytokine-targeted therapies for inflammatory bowel diseases. Br J Pharmacol (2012) 0.85
Involvement of interleukin-15 and interleukin-21, two gamma-chain-related cytokines, in celiac disease. World J Gastroenterol (2009) 0.85
IL-25 prevents and cures fulminant hepatitis in mice through a myeloid-derived suppressor cell-dependent mechanism. Hepatology (2013) 0.84
Reprogramming the immune system in IBD. Dig Dis (2012) 0.84
Post-endoscopic retrograde cholangio-pancreatography pancreatitis: is time for a new preventive approach? World J Gastroenterol (2012) 0.84
Genetic and pathogenetic insights into inflammatory bowel disease. Curr Gastroenterol Rep (2003) 0.83
Molecular basis of the potential of mesalazine to prevent colorectal cancer. World J Gastroenterol (2008) 0.83
Interleukin-21 in immune and allergic diseases. Inflamm Allergy Drug Targets (2012) 0.83
The role of interleukin 17 in Crohn's disease-associated intestinal fibrosis. Fibrogenesis Tissue Repair (2013) 0.83
Interleukin-21 in cancer immunotherapy: Friend or foe? Oncoimmunology (2012) 0.83
A correlation between knee cartilage degradation observed by arthroscopy and synovial proteinases activities. Clin Biochem (2003) 0.83
Targeting IL-23 and Th17-cytokines in inflammatory bowel diseases. Curr Pharm Des (2010) 0.82
The TGF-β/Smad System in IBD Pathogenesis. Inflamm Bowel Dis (2015) 0.82
Inhibition of colon carcinogenesis by 2-methoxy-5-amino-N-hydroxybenzamide, a novel derivative of mesalamine. Gastroenterology (2009) 0.82
Targeting interleukin-21 in immune-mediated pathologies. Curr Drug Targets (2010) 0.82
Pathogenic role of interleukin-21 in psoriasis. Cell Cycle (2009) 0.82
Th17 immune response in IBD: A new pathogenic mechanism. J Crohns Colitis (2008) 0.82
IL-21 in the pathogenesis and treatment of skin diseases. J Dermatol Sci (2010) 0.82
Enhanced expression of interferon regulatory factor-1 in the mucosa of children with celiac disease. Pediatr Res (2003) 0.82
2-methoxy-5-amino-N-hydroxybenzamide sensitizes colon cancer cells to TRAIL-induced apoptosis by regulating death receptor 5 and survivin expression. Mol Cancer Ther (2011) 0.81
The opposing roles of IL-21 and TGFβ1 in chronic inflammatory bowel disease. Biochem Soc Trans (2011) 0.81
High expression of the "A Disintegrin And Metalloprotease" 19 (ADAM19), a sheddase for TNF-α in the mucosa of patients with inflammatory bowel diseases. Inflamm Bowel Dis (2013) 0.81
Role of IL-21 in inflammatory bowel disease. Expert Rev Clin Immunol (2010) 0.81
Colorectal cancer chemoprevention by mesalazine and its derivatives. J Biomed Biotechnol (2012) 0.80
5-aminosalicylic acid enhances anchorage-independent colorectal cancer cell death. Eur J Cancer (2006) 0.80
Tissue inhibitor of metalloproteinase-3 regulates inflammation in human and mouse intestine. Gastroenterology (2012) 0.80
A functional role of flip in conferring resistance of Crohn's disease lamina propria lymphocytes to FAS-mediated apoptosis. Gastroenterology (2006) 0.80
Role of interleukin-21 in inflammation and allergy. Inflamm Allergy Drug Targets (2007) 0.80
Mesalazine negatively regulates CDC25A protein expression and promotes accumulation of colon cancer cells in S phase. Carcinogenesis (2008) 0.80
The IL-12/23/STAT Axis as a Therapeutic Target in Inflammatory Bowel Disease: Mechanisms and Evidence in Man. Dig Dis (2015) 0.79
The challenges of stratifying patients for trials in inflammatory bowel disease. Trends Immunol (2013) 0.79
Psoriasis, from pathogenesis to therapeutic strategies: IL-21 as a novel potential therapeutic target. Curr Pharm Biotechnol (2012) 0.79
Antisense approach to inflammatory bowel disease: prospects and challenges. Drugs (2015) 0.79
Interleukin-25 negatively controls pathogenic responses in the gut. Inflamm Allergy Drug Targets (2011) 0.78
Interleukin-25 fails to activate STAT6 and induce alternatively activated macrophages. Immunology (2010) 0.78
Smad7 antisense oligonucleotide-based therapy for inflammatory bowel diseases. Dig Liver Dis (2013) 0.77
Th17-cytokine blockers as a new approach for treating inflammatory bowel disease. Ann Med (2010) 0.77
Frequency and Cause of Persistent Symptoms in Celiac Disease Patients on a Long-term Gluten-free Diet. J Clin Gastroenterol (2016) 0.77
Appropriate nutrient supplementation in celiac disease. Ann Med (2013) 0.77